HEALTH PROFESSIONAL · SOURCE READING

Dabrafenib

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Melanoma / Systematic Treatment for Unresectable Stage III, Stage IV, and Recurrent Disease / Signal transduction inhibitors / BRAF inhibitors

Dabrafenib is an orally available, small-molecule, selective BRAF inhibitor that was approved by the FDA in 2013. An international multicenter trial (BREAK-3 [NCT01227889]) showed that dabrafenib improved PFS when compared with dacarbazine.[26]

Source links and citations

Studies cited in this source section

Source citation is not a determination that a study applies to you.

NCT01227889 · design, results and side effects

Publication references

Read the original reference and check its publication notices.

PubMed 22735384 · Original source

Preserved source evidence · Not medical advice